Lv11
40 积分 2022-07-31 加入
600- vs 400-mg First-Line Ribociclib in Hormone Receptor–Positive/ERBB2-Negative Advanced Breast Cancer
1天前
待确认
Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial
11天前
已完结
Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
11天前
已完结
Efficacy and Tolerability of Eravacycline in Bacteremic Patients with Complicated Intra-Abdominal Infection: A Pooled Analysis from the IGNITE1 and IGNITE4 Studies
16天前
已完结
Eravacycline: a new treatment option for complicated intra-abdominal infections in the age of multidrug resistance
16天前
已完结
Eravacycline: a comprehensive review of in vitro activity, clinical efficacy, and real-world applications
16天前
已完结
Camrelizumab Plus Famitinib versus Camrelizumab Alone and Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer: A Randomized, Phase II Study
1个月前
已完结
What every intensivist should know about ciprofol
2个月前
已完结
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
3个月前
已完结
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study
4个月前
已完结
皖公网安备34019202002308
